Board of Directors
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.
Targeting hidden tumor vulnerabilities through synthetic lethality, metabolic and epigenetic dependencies, and precision oncology approaches designed to overcome tumor growth and drug resistance.
Target the main oncogenic driver of uveal melanoma
Improve efficacy and durability of TOP1 ADCs
Exploit a metabolic vulnerability in MTAP-deleted cancers
Simultaneously target key epigenetic drivers of cancer
Advancing precision oncology therapies and rational combinations designed to target the core vulnerabilities and drivers of molecularly defined cancers.
Focused on patients with limited treatment options, our trials use precision medicine and predictive biomarkers to accelerate the development of targeted therapies.